Discovery of an RNF126-Dependent Polθ Degrader Exhibiting In Vivo Activity in an HR-Deficient Tumor Model

DNA polymerase theta (Polθ), a multidomain DNA repair enzyme, has emerged as a promising synthetic-lethal target in homologous recombination (HR)-deficient tumors, yet current inhibitors directed at either its helicase or polymerase domain may not fully suppress the functions of the intact protein. Here, we report PR-6, a RNF126-dependent Polθ degrader identified through comparative degrader screening and structural optimization. In BRCA1-deficient MDA-MB-436 cells, PR-6 induced, concentration- and time-dependent Polθ degradation via an RNF126- and ubiquitin-proteasome-dependent mechanism. Compared with the Polθ helicase inhibitor AB25583 under the tested cellular conditions, PR-6 exhibited greater antiproliferative activity and induced more pronounced DNA damage and apoptosis. Moreover, PR-6 synergized with Olaparib in vitro and markedly potentiated its antitumor efficacy in an MDA-MB-436 xenograft model without overt toxicity. These findings support PR-6 as the first degrader probe for interrogating Polθ biology and provide proof of concept for Polθ degradation as a complementary strategy in HR-deficient tumors.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.jmedchem.6c02430
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of an RNF126-Dependent Polθ Degrader Exhibiting In Vivo Activity in an HR-Deficient Tumor Model

Hua Xiang, Guoshun Luo, Maoxu Xiao, Xinyan Liu et al.
4 links
Journal of Medicinal Chemistry
Protein Degradation and Inhibitors
article

Discovery of an RNF126-Dependent Polθ Degrader Exhibiting In Vivo Activity in an HR-Deficient Tumor Model

Hua Xiang, Guoshun Luo, Maoxu Xiao, Xinyan Liu, Luyu Ma, Mingjin Luo, Xiaofan Ge, Zhonglin Zhang
article en

Abstract

DNA polymerase theta (Polθ), a multidomain DNA repair enzyme, has emerged as a promising synthetic-lethal target in homologous recombination (HR)-deficient tumors, yet current inhibitors directed at either its helicase or polymerase domain may not fully suppress the functions of the intact protein. Here, we report PR-6, a RNF126-dependent Polθ degrader identified through comparative degrader screening and structural optimization. In BRCA1-deficient MDA-MB-436 cells, PR-6 induced, concentration- and time-dependent Polθ degradation via an RNF126- and ubiquitin-proteasome-dependent mechanism. Compared with the Polθ helicase inhibitor AB25583 under the tested cellular conditions, PR-6 exhibited greater antiproliferative activity and induced more pronounced DNA damage and apoptosis. Moreover, PR-6 synergized with Olaparib in vitro and markedly potentiated its antitumor efficacy in an MDA-MB-436 xenograft model without overt toxicity. These findings support PR-6 as the first degrader probe for interrogating Polθ biology and provide proof of concept for Polθ degradation as a complementary strategy in HR-deficient tumors.

Journal of Medicinal Chemistry
China Pharmaceutical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province
Good health and well-being
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon